• 1
    Ansari D, Chen B-C, Dong L, Zhou M-T, Andersson R. Pancreatic cancer: translational research aspects and clinical implications. World J Gastroenterol 2012; 18: 141724.
  • 2
    Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 1996; 223: 2739.
  • 3
    Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet 2011; 378: 60720.
  • 4
    Nakao A, Takeda S, Inoue S et al. Indications and techniques of extended resection for pancreatic cancer. World J Surg 2006; 30: 97682.
  • 5
    Kato K, Kondo S, Hirano S et al. Adjuvant surgical therapy for patients with initially-unresectable pancreatic cancer with long-term favorable responses to chemotherapy. J Hepatobiliary Pancreat Sci 2011; 18: 7126.
  • 6
    Obeid M, Tesniere A, Ghiringhelli F et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13: 5461.
  • 7
    Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011; 8: 15160.
  • 8
    Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8: 5973.
  • 9
    Brode S, Cooke A. Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. Crit Rev Immunol 2008; 28: 10926.
  • 10
    Yue ZQ, Liu YP, Ruan JS, Zhou L, Lu Y. Tumor-associated macrophages: a novel potential target for cancer treatment. Chin Med J 2012; 125: 330511.
  • 11
    Sobin LH, Wittekind CH. International Union Against Cancer. TNM Classification of Malignant Tumors. NewYork: Wiley-Liss, 2002; 604.
  • 12
    Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 20516.
  • 13
    Evans DB, Rich TA, Byrd DR et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992; 127: 13359.
  • 14
    Cho Y, Miyamoto M, Kato K et al. CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res 2003; 63: 15559.
  • 15
    Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11: 21533.
  • 16
    Noguchi T, Kato T, Wang L et al. Intracellular tumor-associated antigens represent effective targets for passive immunotherapy. Cancer Res 2012; 72: 167282.
  • 17
    Rubner Y, Wunderlich R, Rühle PF et al. How does ionizing irradiation contribute to the induction of anti-tumor immunity? Front Oncol 2012; 2: 75.
  • 18
    Fukunaga A, Miyamoto M, Cho Y et al. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 2004; 28: 2631.
  • 19
    Hiraoka K, Miyamoto M, Cho Y et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 2006; 94: 27580.
  • 20
    Tsuchikawa T, Miyamoto M, Yamamura Y, Shichinohe T, Hirano S, Kondo S. The immunological impact of neoadjuvant chemotherapy on the tumor microenvironment of esophageal squamous cell carcinoma. Ann Surg Oncol 2012; 19: 17139.
  • 21
    Muranski P, Boni A, Wrzesinski C et al. Increased intensity lymphodepletion and adoptive immunotherapy – how far can we go? Nat Clin Pract Oncol 2006; 3: 66881.
  • 22
    Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 19604.